REBECCA REILLY: Open Payments
NPI 1952983009 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,240 in 79 payments from 27 companies in 2025. Trend: 2023 $1,516 · 2024 $1,186 · 2025 $2,240
Food & beverage: $1,897Honoraria: $300Education: $43
| Company | Payments | Amount |
|---|---|---|
| Chiesi USA, Inc. | 1 | $300 |
| Novo Nordisk Inc | 9 | $246 |
| Amgen Inc. | 7 | $213 |
| Dexcom, Inc. | 9 | $204 |
| AstraZeneca Pharmaceuticals LP | 7 | $189 |
| ABBVIE INC. | 9 | $166 |
| Abbott Laboratories | 1 | $155 |
| Mannkind Corporation | 3 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| ViiV Healthcare Company | 2 | $61 |
Products named: JUXTAPID, Ozempic, FREESTYLE LIBRE 3, AIRSUPRA, REPATHA, DEXCOM G7 GSS (161), UBRELVY, AFREZZA.
Industry payments across NV — which companies pay providers there.
